Deal Tracker · Countries
Egypt pharma deals
27 pharma deals involving Egypt — companies based there or deals covering the market — tracked by EPT: localization, M&A & investment. Most active: Eva Pharma, Afreximbank, Rameda & VACSERA. Latest: Eva Pharma → Med Right (Partnership / Collaboration, 18 Nov 2026).
- EPT has tracked 27 Egypt pharma deals (2021–2026), 20 of them announced in 2026.
- The most common structures are localization (30%), m&a (19%) & investment (15%).
- Values were disclosed for 5 of 27 deals, totalling $560.5m; the largest is DKSH → NewBridge Pharmaceuticals ($390m, 19 Oct 2026).
- The most active companies: Eva Pharma (4), Afreximbank (2), Minapharm (2) & Rameda (2).
- Eva Pharma → Med RightPartnership / Collaboration · MENA · Undisclosed · 18 Nov 2026
- Gilead Sciences → Eva PharmaLicensing · Global (LMICs) · Royalty-free · 16 Nov 2026
- Afreximbank → AMA Medical ManufacturingEquity / Investment · Latin America · Undisclosed · 9 Nov 2026
- Dawah Pharma → HoldiPharmaJoint venture · MENA · Undisclosed · 5 Nov 2026
- Eva Pharma → United PharmaciesDistribution · GCC · Undisclosed · 26 Oct 2026
- Walvax → Vaccine and Biotechnology CityTechnology transfer / Localization · MENA · Undisclosed · 26 Oct 2026
- Rameda → Art PharmaM&A / Acquisition · MENA · $20m · 26 Oct 2026
- Marcyrl Pharmaceutical Industries → Mubadala BioTechnology transfer / Localization · GCC · 21 Oct 2026
- RMBV → ATCO PharmaEquity / Investment · MENA · Undisclosed · 21 Oct 2026
- EastPharma → SanofiM&A / Acquisition · Africa · 20 Oct 2026
- DKSH → NewBridge PharmaceuticalsM&A / Acquisition · MENA · $390m · 19 Oct 2026
- Eva Pharma → CCL PharmaceuticalsPartnership / Collaboration · Southeast Asia · Undisclosed · 17 Sept 2026
- CEPI → MinapharmPartnership / Collaboration · Africa · $16.5m · 27 Aug 2026
- Alfasigma → Nordic PharmaM&A / Acquisition · Global ex-US · See terms · 9 Aug 2026
- Gypto Pharma → BachaDistribution · Africa · Undisclosed · 4 Aug 2026
- Bausch Health → AUG PharmaM&A / Acquisition · GCC · Undisclosed · 12 Jul 2026
- Daewoong Pharmaceutical → Arcera Life SciencesLicensing · MENA · $94m · 29 Jun 2026
- Egyptian Ministry of Health and Population / Egyptian Drug Authority → International partnersTechnology transfer / Localization · MENA · Undisclosed · 16 Jun 2026
- LVP Pharma → RamedaEquity / Investment · MENA · EGP 847m for 8.3% · 10 Jun 2026
- Minhai Biotechnology → VACSERATechnology transfer / Localization · Africa · 1 Jan 2026
- Bayer → Minapharm PharmaceuticalsTechnology transfer / Localization · MENA · Undisclosed · 15 Nov 2025
- BioGeneric Pharma → GWMTechnology transfer / Localization · GCC · Undisclosed · 30 Jul 2025
- Apex Pharma → CIGALAH HealthcareDistribution · GCC · Undisclosed · 17 Apr 2025
- Sandoz → SEDICOTechnology transfer / Localization · MENA · Undisclosed · 6 Mar 2025
- Afreximbank → Med Aditus Pharmaceutical KenyaEquity / Investment · Africa · $40m · 29 Nov 2024
- Huadong Medicine → JulpharPartnership / Collaboration · MENA · Undisclosed · 25 Jun 2022
- Sinovac Biotech → VACSERATechnology transfer / Localization · Africa · Undisclosed · 1 Apr 2021
Most active companies
Eva Pharma (4) · Afreximbank (2) · Minapharm (2) · Rameda (2) · VACSERA (2)
Largest disclosed deals
- DKSH → NewBridge Pharmaceuticals · $390m · M&A / Acquisition · 19 Oct 2026
- Daewoong Pharmaceutical → Arcera Life Sciences · $94m · Licensing · 29 Jun 2026
- Afreximbank → Med Aditus Pharmaceutical Kenya · $40m · Equity / Investment · 29 Nov 2024
Questions
- How many Egypt pharma deals has EPT tracked?
- 27 as of 18 Nov 2026, covering 2021–2026; 20 were announced in 2026. The most recent is Eva Pharma → Med Right (Partnership / Collaboration, 18 Nov 2026).
- What types of Egypt pharma deals are most common?
- Technology transfer / Localization: 8 (30%); M&A / Acquisition: 5 (19%); Equity / Investment: 4 (15%); Partnership / Collaboration: 4 (15%).
- Which companies are most active in Egypt pharma deals?
- Eva Pharma (4 deals), Afreximbank (2 deals), Minapharm (2 deals), Rameda (2 deals), VACSERA (2 deals).
- What is the largest disclosed Egypt pharma deal?
- DKSH → NewBridge Pharmaceuticals: $390m (M&A / Acquisition, 19 Oct 2026); Daewoong Pharmaceutical → Arcera Life Sciences: $94m (Licensing, 29 Jun 2026); Afreximbank → Med Aditus Pharmaceutical Kenya: $40m (Equity / Investment, 29 Nov 2024). Values are as announced by the parties.
Browse deals
By region
GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)
By country
Saudi Arabia (69) · UAE (61) · China (31) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)
By deal type
Licensing (56) · Distribution (41) · Technology transfer / Localization (39) · Partnership / Collaboration (35) · M&A / Acquisition (21) · Equity / Investment (18) · Joint venture (11) · Supply / Manufacturing (10)
Popular searches
MENA pharma licensing deals (25) · Saudi Arabia pharma licensing deals (24) · GCC pharma distribution deals (21) · GCC pharma partnerships (19) · China pharma licensing deals (17) · UAE pharma distribution deals (17) · GCC pharma localization & tech-transfer deals (15) · Saudi Arabia pharma distribution deals (14) · UAE pharma partnerships (13) · UAE pharma licensing deals (12) · Global (LMICs) pharma licensing deals (11) · India pharma licensing deals (11) · GCC pharma licensing deals (10) · MENA pharma partnerships (10) · Saudi Arabia pharma localization & tech-transfer deals (10) · MENA pharma localization & tech-transfer deals (9) · United States pharma licensing deals (9) · Egypt pharma localization & tech-transfer deals (8) · Saudi Arabia pharma partnerships (8) · CIS & Central Asia pharma localization & tech-transfer deals (7) · Kazakhstan pharma localization & tech-transfer deals (7) · MENA pharma distribution deals (7) · MENA pharma M&A deals (7) · United States pharma distribution deals (7)
By company
ADCAN Pharma (13) · Mubadala Bio (8) · Jamjoom Pharma (7) · SPIMACO (7) · Arcera Life Sciences (6) · Hikma Pharmaceuticals (6) · Bio-Thera Solutions (6) · Avalon Pharma (5) · Tabuk Pharmaceuticals (5) · Local Content and Government Procurement Authority (5) · Kazakhstan Ministry of Health (5) · Eva Pharma (4) · Sandoz (4) · Department of Health – Abu Dhabi (4) · Biocon (4) · Groupe Saidal (4) · Gilead Sciences (3) · Dr. Reddy's Laboratories (3) · Emirates Drug Establishment (3) · Novo Nordisk (3) · Khazaen Economic City (3) · Galenicum (3) · Roche (3) · Laprophan (3) · Sanofi (3) · Gen İlaç (3) · Taiba Healthcare (3) · Dar Al Dawa (3) · Lifera (3) · Celltrion (2) · Viatris (2) · Rem3dy Health (2) · AMA Medical Manufacturing (2) · Afreximbank (2) · M42 (2) · Abbott (2) · DKSH (2) · Adalvo (2) · Rameda (2) · Menarini (2) · Korea United Pharm (2) · Samsung Bioepis (2) · AstraZeneca (2) · MS Pharma (2) · LifePharma (2) · Duopharma Biotech (2) · JCR Pharmaceuticals (2) · Philex Pharmaceuticals (2) · Lotus Pharmaceutical (2) · Elpen (2) · Dhofar Pharmaceutical Industries (2) · Accord Healthcare (2) · CCL Pharmaceuticals (2) · Abdi İbrahim (2) · Nordic Pharma (2) · UNIMED Laboratories (2) · Minapharm (2) · SaudiVax (2) · Faes Farma (2) · AJA Pharma (2) · VACSERA (2) · Bayer (2) · Shanghai Henlius Biotech (2) · Julphar (2)
By therapeutic area
Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)